^
Association details:
| Biomarker: | ROS1 rearrangement + ROS1 F2004L |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with ROS1-rearranged lung adenocarcinoma
Excerpt:
We report a ROS1-rearranged stage ⅢB lung adenocarcinoma patient who was resistant to ceritinib after developing a secondary ROS1 F2004L mutation….The patient responded well to lorlatinib and had no relapse.
DOI:
10.1136/jitc-2020-001967
